Your session is about to expire
← Back to Search
Behavioural Intervention
Special Light Treatment for Multiple Myeloma
N/A
Recruiting
Led By Mariana Figueiro, PhD
Research Sponsored by Icahn School of Medicine at Mount Sinai
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Scheduled to undergo their first Autologous Stem Cell Transplant procedure
21 years or older
Must not have
Active infection including COVID-19 infection
Severe sleep disorders
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at baseline, or during the hospital visit prior to transplant
Summary
This trial will test how a special light treatment can help Multiple Myeloma patients with their sleep, inflammation and symptoms. 200 people will receive this light over a 2-month period.
Who is the study for?
This trial is for adults over 21 with multiple myeloma who are English-speaking and ready for their first autologous stem cell transplant. They must be able to consent to the study. Those pregnant, with eye diseases affecting light processing, other recent cancers, severe sleep or psychological disorders, history of bipolar/manic episodes, past light therapy use or active infections like COVID-19 cannot join.
What is being tested?
The study tests two lighting conditions on circadian rhythm in multiple myeloma patients during stem cell transplantation. It aims to see if 'Circadian Effective Lighting' versus 'Circadian Ineffective Lighting' can improve sleep efficiency, melatonin levels in urine, reduce inflammation and symptom burden over two months.
What are the potential side effects?
Since this trial involves lighting conditions rather than drugs or invasive procedures, side effects may include discomfort from the light settings or potential disruption of normal sleep patterns due to changes in exposure to certain types of artificial light.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am scheduled for my first stem cell transplant using my own cells.
Select...
I am 21 years old or older.
Select...
I am 21 years old or older.
Select...
I have been diagnosed with Multiple Myeloma.
Select...
I am scheduled for my first stem cell transplant using my own cells.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I do not have an active infection, including COVID-19.
Select...
I have a severe sleep disorder.
Select...
I have been diagnosed with another cancer within the last 5 years.
Select...
I have an eye condition that affects how I see light.
Select...
I have used light therapy before.
Select...
I have a history of bipolar disorder or manic episodes.
Select...
I have had a stem cell transplant using my own cells.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at 3 days following engraftment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 3 days following engraftment
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Changes in Urinary Melatonin
Secondary study objectives
Circadian Light levels measured with Daysimeter (light monitor) at 3 days after engraftment
Circadian Light levels measured with Daysimeter (light monitor) at 4 weeks after engraftment
Circadian Light levels measured with Daysimeter (light monitor) at 7 days post-transplant
+26 moreTrial Design
2Treatment groups
Active Control
Placebo Group
Group I: Circadian Effective Lighting (CEL)Active Control1 Intervention
The CEL will be performed in hospital sites over a 2-month period.
Group II: Circadian Ineffective Lighting (CIL)Placebo Group1 Intervention
The comparator lighting will be performed identical to Arm 1, at specified lower levels of lighting.
Find a Location
Who is running the clinical trial?
Icahn School of Medicine at Mount SinaiLead Sponsor
902 Previous Clinical Trials
541,802 Total Patients Enrolled
10 Trials studying Multiple Myeloma
1,711 Patients Enrolled for Multiple Myeloma
Mariana Figueiro, PhDPrincipal InvestigatorIcahn School of Medicine at Mount Sinai
10 Previous Clinical Trials
675 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You must be proficient in English, able to communicate effectively.You have a serious mental health condition.I am 21 years old or older.I am scheduled for my first stem cell transplant using my own cells.I do not have an active infection, including COVID-19.I have a severe sleep disorder.I have been diagnosed with another cancer within the last 5 years.I have an eye condition that affects how I see light.I have used light therapy before.I am 21 years old or older.I have been diagnosed with Multiple Myeloma.You have the capacity to consent.I am scheduled for my first stem cell transplant using my own cells.I have a history of bipolar disorder or manic episodes.I have had a stem cell transplant using my own cells.
Research Study Groups:
This trial has the following groups:- Group 1: Circadian Effective Lighting (CEL)
- Group 2: Circadian Ineffective Lighting (CIL)
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger